Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 1, pp 33–40 | Cite as

FKBP1A rs6041749 polymorphism is associated with allograft function in renal transplant patients

  • Zhuo Wu
  • Qinxia Xu
  • Xiaoyan Qiu
  • Luyang Xu
  • Zheng Jiao
  • Ming Zhang
  • Mingkang Zhong
Pharmacogenetics
  • 80 Downloads

Abstract

Aim

To investigate the potential impact of single-nucleotide polymorphisms (SNPs) in the FK506-binding protein (FKBP)-calcineurin (CaN)-nuclear factor of activated T cells (NFAT) signaling pathway on the efficacy and safety of tacrolimus (TAC) in Chinese renal transplant patients.

Methods

Seventy-seven tag SNPs were detected in 146 patients who were on TAC-based maintenance immunosuppression and who followed up for at least 2 years. The relationships of these polymorphisms with clinical outcomes such as acute rejection, acute nephrotoxicity, pneumonia, and estimated glomerular filtration rate (eGFR) were explored. For the FKBP1A rs6041749 polymorphism, which has a significant association with renal function over time, a preliminary functional analysis was performed using a dual-luciferase reporter gene system.

Results

The patients with FKBP1A rs6041749 TT genotype had a more stable eGFR level than CC and CT carriers (P = 2.08 × 10−8) during the 2 years following transplantation. Dual-luciferase reporter assay results showed that the rs6041749 C variant could enhance the relative luciferase activity compared with the T variant, which indicated that the rs6041749 C allele may increase the FKBP1A gene transcription. In addition, we did not find any association between these genetic variants and the risk of acute rejection, acute nephrotoxicity, and pneumonia in renal transplant patients receiving TAC-based immunosuppression.

Conclusions

FKBP1A rs6041749 C allele carriers are at higher risk for eGFR deterioration. The variant might serve as a biomarker to predict allograft function in renal transplant patients.

Keywords

FKBP Polymorphisms Tacrolimus eGFR  Renal transplantation 

Notes

Contribution of the authors

XYQ conceived the study. XYQ, ZJ, and MKZ participated in research design. XYQ, QXX, LYX, ZJ, and MZ contributed to acquisition of the patients’ data. ZW performed the research and analyzed the data. ZW and XYQ drafted and all the authors revised the manuscript.

Funding information

Dr. Xiaoyan Qiu had support from the National Natural Science Foundation of China (No. 81302854) and Natural Science Foundation of Shanghai (No. 13ZR1405200).

Prof. Zheng Jiao was supported by the National Natural Science Foundation of China (No. 81573505) and the Guidance Project of Shanghai Municipal Science and Technology Commission (15411968000) and “Weak Discipline Construction Project” (No. 2016ZB0301–01) of Shanghai Municipal Commission of Health and Family Planning.

Prof. Mingkang Zhong was supported by “2016 Key Clinical Program of Clinical Pharmacy.”

Compliance with ethical standards

The study was performed in accordance with the Declaration of Helsinki and its amendments. Protocols were approved by the Ethics Committee of Huashan Hospital, Fudan University and written informed consents were obtained from all subjects.

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

228_2018_2546_MOESM1_ESM.docx (143 kb)
ESM 1 (DOCX 142 kb)

References

  1. 1.
    Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23(10):563–585.  https://doi.org/10.1097/FPC.0b013e328364db84 CrossRefGoogle Scholar
  2. 2.
    van Gelder T, van Schaik RH, Hesselink DA (2014) Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol 10(12):725–731.  https://doi.org/10.1038/nrneph.2014.172 CrossRefGoogle Scholar
  3. 3.
    MacMillan D (2013) FK506 binding proteins: cellular regulators of intracellular Ca2+ signalling. Eur J Pharmacol 700(1–3):181–193.  https://doi.org/10.1016/j.ejphar.2012.12.029 CrossRefGoogle Scholar
  4. 4.
    Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF (2001) Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 1(4):325–333CrossRefGoogle Scholar
  5. 5.
    Jiang H, Xiong F, Kong S, Ogawa T, Kobayashi M, Liu JO (1997) Distinct tissue and cellular distribution of two major isoforms of calcineurin. Mol Immunol 34(8–9):663–669CrossRefGoogle Scholar
  6. 6.
    Miyata H, Satouh Y, Mashiko D, Muto M, Nozawa K, Shiba K, Fujihara Y, Isotani A, Inaba K, Ikawa M (2015) Sperm calcineurin inhibition prevents mouse fertility with implications for male contraceptive. Science 350(6259):442–445.  https://doi.org/10.1126/science.aad0836 CrossRefGoogle Scholar
  7. 7.
    Klee CB, Ren H, Wang X (1998) Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem 273(22):13367–13370CrossRefGoogle Scholar
  8. 8.
    Macian F (2005) NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5(6):472–484.  https://doi.org/10.1038/nri1632 CrossRefGoogle Scholar
  9. 9.
    Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G, Gress TM, Ellenrieder V (2006) Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 25(15):3714–3724.  https://doi.org/10.1038/sj.emboj.7601246 CrossRefGoogle Scholar
  10. 10.
    Rao A, Luo C, Hogan PG (1997) Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15:707–747.  https://doi.org/10.1146/annurev.immunol.15.1.707 CrossRefGoogle Scholar
  11. 11.
    Paradowska-Gorycka A, Romanowska-Prochnicka K, Haladyj E, Manczak M, Maslinski S, Olesinska M (2015) Association of the Smad3 and NFATc2 gene polymorphisms and their serum levels with susceptibility to rheumatoid arthritis in Polish cohorts. Clin Exp Immunol 179(3):444–453.  https://doi.org/10.1111/cei.12482 CrossRefGoogle Scholar
  12. 12.
    Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimaki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M (2013) Genetic loci associated with Alzheimer’s disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort. PLoS One 8(4):e59676.  https://doi.org/10.1371/journal.pone.0059676 CrossRefGoogle Scholar
  13. 13.
    He ZH, Hu Y, Li YC, Bao DP, Ruiz JR, Lucia A (2010) Polymorphisms in the calcineurin genes are associated with the training responsiveness of cardiac phenotypes in Chinese young adults. Eur J Appl Physiol 110(4):761–767.  https://doi.org/10.1007/s00421-010-1558-8 CrossRefGoogle Scholar
  14. 14.
    He ZH, Hu Y, Wang HY, Li YC, Lu YL, Zhang L, Bao BP, Ruiz JR, Lucia A (2010) Are calcineurin genes associated with endurance phenotype traits? Eur J Appl Physiol 109(3):359–369.  https://doi.org/10.1007/s00421-010-1361-6 CrossRefGoogle Scholar
  15. 15.
    Gu H, Gong J, Qiu W, Cao H, Xu J, Chen S, Chen Y (2011) Association of a tandem repeat polymorphism in NFATc1 with increased risk of perimembranous ventricular septal defect in a Chinese population. Biochem Genet 49(9–10):592–600.  https://doi.org/10.1007/s10528-011-9434-8 CrossRefGoogle Scholar
  16. 16.
    Mitchell AL, Boe Wolff A, MacArthur K, Weaver JU, Vaidya B, Swedish Addision Registry Study G, Sophie Bensing on behalf of The Swedish Addison Registry Study G, Erichsen MM, Darlay R, Husebye ES, Cordell HJ, Pearce SH (2015) Linkage analysis in autoimmune Addison’s disease: NFATC1 as a potential novel susceptibility locus. PLoS One 10(6):e0123550.  https://doi.org/10.1371/journal.pone.0123550 CrossRefGoogle Scholar
  17. 17.
    Shinozaki G, Jowsey S, Amer H, Biernacka J, Colby C, Walker D, Black J, Rundell J, Stegall M, Mrazek DA (2011) Relationship between FKBP5 polymorphisms and depression symptoms among kidney transplant recipients. Depress Anxiety 28(12):1111–1118.  https://doi.org/10.1002/da.20879 CrossRefGoogle Scholar
  18. 18.
    Chen Y, Sampaio MS, Yang JW, Min D, Hutchinson IV (2012) Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 93(3):325–330.  https://doi.org/10.1097/TP.0b013e31823f7f26 CrossRefGoogle Scholar
  19. 19.
    Ciliao HL, Camargo-Godoy RBO, de Souza MF, Dos Reis MB, Iastrenski L, Alvares Delfino VD, Rogatto SR, de Syllos Colus IM (2017) Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients. J Toxicol Environ Health A 80(13–15):661–671.  https://doi.org/10.1080/15287394.2017.1286922 CrossRefGoogle Scholar
  20. 20.
    Wu Z, Xu Q, Qiu X, Jiao Z, Zhang M, Zhong M (2017) FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients. Eur J Clin Pharmacol 73(1):39–47.  https://doi.org/10.1007/s00228-016-2140-z CrossRefGoogle Scholar
  21. 21.
    Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ (2007) Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 7(3):518–526.  https://doi.org/10.1111/j.1600-6143.2006.01688.x CrossRefGoogle Scholar
  22. 22.
    Group KDIGOKCW (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150.  https://doi.org/10.1038/kisup.2012.73 CrossRefGoogle Scholar
  23. 23.
    Xu Q, Qiu X, Jiao Z, Zhang M, Chen J, Zhong M (2017) NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients. Pharmacogenomics 18(4):381–392.  https://doi.org/10.2217/pgs-2016-0171 CrossRefGoogle Scholar
  24. 24.
    Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, Mathieson T, Lemeer S, Schnatbaum K, Reimer U, Wenschuh H, Mollenhauer M, Slotta-Huspenina J, Boese JH, Bantscheff M, Gerstmair A, Faerber F, Kuster B (2014) Mass-spectrometry-based draft of the human proteome. Nature 509(7502):582–587.  https://doi.org/10.1038/nature13319 CrossRefGoogle Scholar
  25. 25.
    Speidel JT, Xu M, Abdel-Rahman SZ (2017) Differential effect of ABCB1 haplotypes on promoter activity. Pharmacogenet Genomics.  https://doi.org/10.1097/FPC.0000000000000323
  26. 26.
    Zhang Q, Wang W, Xu W, Du M, Ma G, Liu H, Chu H, Tong NA, Wang M, Shao J, Zhang Z, Yuan L, Qian J (2018) Genetic variations in the 3′-untranslated regions of genes involved in the cell cycle and apoptosis pathways affect bladder cancer risk. Cancer Genomics Proteomics 15(1):67–72.  https://doi.org/10.21873/cgp.20066 Google Scholar
  27. 27.
    Pirooz HJ, Jafari N, Rastegari M, Fathi-Roudsari M, Tasharrofi N, Shokri G, Sazgar H, Kouhkan F (2017) Functional SNP in microRNA-491-5p binding site of MMP9 3′-UTR affects cancer susceptibility. J Cell Biochem.  https://doi.org/10.1002/jcb.26471
  28. 28.
    Shi Y, Chen X, Xi B, Yu X, Ouyang J, Han C, Qin Y, Wu D, Shen H (2017) SNP rs3202538 in 3′UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population. Cancer Cell Int 17:81.  https://doi.org/10.1186/s12935-017-0449-z CrossRefGoogle Scholar
  29. 29.
    Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49(3):141–175CrossRefGoogle Scholar
  30. 30.
    Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 49(4):207–221.  https://doi.org/10.2165/11317550-000000000-00000 CrossRefGoogle Scholar
  31. 31.
    Wang Z, Yang H, Si S, Han Z, Tao J, Chen H, Ge Y, Guo M, Wang K, Tan R, Wei JF, Gu M (2017) Polymorphisms of nucleotide factor of activated T cells cytoplasmic 2 and 4 and the risk of acute rejection following kidney transplantation. World J Urol 36:111–116.  https://doi.org/10.1007/s00345-017-2117-2 CrossRefGoogle Scholar
  32. 32.
    Pouche L, Koitka M, Stojanova J, Woillard JB, Monchaud C, Villeneuve C, Essig M, Abraham J, Le Meur Y, Rerolle JP, Kamar N, Rostaing L, Merville P, Gandia P, Bouchet S, Petersen BS, Marquet P, Picard N (2016) A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. Pharmacogenomics 17(4):375–391.  https://doi.org/10.2217/pgs.15.181 CrossRefGoogle Scholar
  33. 33.
    Hoffmann S, Park J, Jacobson LM, Muehrer RJ, Lorentzen D, Kleiner D, Becker YT, Hullett DA, Mannon R, Kirk AD, Becker BN (2004) Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 66(4):1686–1693.  https://doi.org/10.1111/j.1523-1755.2004.00936.x CrossRefGoogle Scholar
  34. 34.
    Zhao CY, Jiao Z, Mao JJ, Qiu XY (2015) External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 81:891–907.  https://doi.org/10.1111/bcp.12830 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Zhuo Wu
    • 1
  • Qinxia Xu
    • 1
  • Xiaoyan Qiu
    • 1
  • Luyang Xu
    • 1
  • Zheng Jiao
    • 1
  • Ming Zhang
    • 2
  • Mingkang Zhong
    • 1
  1. 1.Department of Pharmacy, Huashan HospitalFudan UniversityShanghaiChina
  2. 2.Department of Nephrology, Huashan HospitalFudan UniversityShanghaiChina

Personalised recommendations